COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-smal...
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-small cell lung cancer
About this item
Full title
Author / Creator
Mehlman, Camille , Swalduz, Aurelie , Monnet, Isabelle , Morin, Clara , Wislez, Marie , Guisier, Florian , Curcio, Hubert , Du Rusquec, Pauline , Cortot, Alexis B , Gounant, Valerie , Abbar, Baptiste , Duchemann, Boris , Giroux-Leprieur, Etienne , Pierret, Thomas , Quilot, Fleur-Marie , Cadranel, Jacques and Fallet, Vincent
Publisher
England
Journal title
Language
English
Formats
Publication information
Publisher
England
More information
Scope and Contents
Contents
The emergence of diverse resistance mechanisms after osimertinib therapy, including on-target epidermal growth factor receptor (EGFR) mutations and off-target alterations, warrants investigation of novel therapeutics to overcome these challenges and improve patient outcomes.
COMPOSIT was a French, retrospective, multicenter, cohort study of the...
Alternative Titles
Full title
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-small cell lung cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_3149540990
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3149540990
Other Identifiers
ISSN
1083-7159,1549-490X
E-ISSN
1549-490X
DOI
10.1093/oncolo/oyae312
